David F. Penson
Vanderbilt University Medical Center
Quality of lifeCancerInternal medicineUrologySurgeryOncologyIntensive care medicineCystectomyProstateDiseaseProstatectomyMEDLINEProstate cancerBladder cancerProstate-specific antigenPopulationGynecologyFamily medicineMedicineCohort
Publications 831
#1Christopher J.D. Wallis (U of T: University of Toronto)H-Index: 24
#2Zhiguo Zhao (VUMC: Vanderbilt University Medical Center)H-Index: 10
Last. Daniel A. Barocas (VUMC: Vanderbilt University Medical Center)H-Index: 54
view all 20 authors...
Importance null Treatment-related regret is an integrative, patient-centered measure that accounts for morbidity, oncologic outcomes, and anxiety associated with prostate cancer diagnosis and treatment. null Objective null To assess the association between treatment approach, functional outcomes, and patient expectations and treatment-related regret among patients with localized prostate cancer. null Design, setting, and participants null This population-based, prospective cohort study used 5 Su...
#1Ugo De GiorgiH-Index: 56
#2Maha Hussain (NU: Northwestern University)H-Index: 80
Last. Joyce Steinberg (Astellas Pharma)H-Index: 13
view all 14 authors...
BACKGROUND Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with rapidly rising prostate-specific antigen (PSA). The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups. PATIENTS AND METHODS Eligible men with nmCR...
#1Brian De (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Dario Pasalic (University of Texas MD Anderson Cancer Center)H-Index: 8
Last. Karen E. Hoffman (University of Texas MD Anderson Cancer Center)H-Index: 42
view all 10 authors...
PURPOSE/OBJECTIVE(S) High-quality data comparing radical prostatectomy (RP) and external beam radiotherapy plus low dose-rate brachytherapy boost (EBRT-LDR) are lacking. To better inform treatment selection, we compared patient reported functional outcomes (PROs) through 5 years following RP or EBRT-LDR for localized prostate cancer. MATERIALS/METHODS Men were enrolled from 2011-2012 on this multicenter prospective study. Enrollment criteria were: 1) age < 80 years, 2) prostate-specific antigen ...
#1David F. Penson (VUMC: Vanderbilt University Medical Center)H-Index: 82
#2Andrew J. Armstrong (Duke University)H-Index: 62
Last. Celestia S. Higano (Fred Hutchinson Cancer Research Center)H-Index: 88
view all 12 authors...
BACKGROUND In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this protocol-specified subgroup analysis of STRIVE was to investigate the benefit of enzalutamide versus bicalutamide specifically in patients with nmCRPC. METHODS Patients (N = 139) were stratified by dise...
#1Wilson Sui (VUMC: Vanderbilt University Medical Center)H-Index: 9
#2Mary E. Hall (VUMC: Vanderbilt University Medical Center)H-Index: 1
Last. Aaron A. Laviana (University of Texas at Austin)H-Index: 1
view all 9 authors...
Abstract null null Objective null To examine the relationship between hospital volume and the management of bladder cancer variant histology. Variant histologies of bladder cancer are rare which limits the ability for providers to develop expertise however there is a clear hospital and/or surgeon-volume relationship for management of rare or complex surgical and/or medical diseases. null null null Methods null We queried the National Cancer Database from 2004-2016 for all cases of bladder cancer...
#1Christopher J.D. Wallis (VUMC: Vanderbilt University Medical Center)H-Index: 24
#2Daniel D. Joyce (VUMC: Vanderbilt University Medical Center)H-Index: 7
Last. Daniel A. Barocas (VUMC: Vanderbilt University Medical Center)H-Index: 54
view all 8 authors...
Abstract null null Purpose null Financial toxicity is an underappreciated component of cancer survivorship. Treatment-specific out-of-pocket costs for patients undergoing localized prostate cancer treatment have not, to date, been described and may influence patient's decision making. null null null Methods null We performed a retrospective cohort study among commercially-insured patients in the United States with incident prostate cancer from 2013 to 2018. We captured out-of-pocket and total co...
#1Behnam Nabavizadeh (UCSF: University of California, San Francisco)H-Index: 7
#2Nizar Hakam (UCSF: University of California, San Francisco)
Last. Benjamin N. Breyer (UCSF: University of California, San Francisco)H-Index: 44
view all 8 authors...
Abstract null null Objective null To identify the current formats of standardized letters of recommendation (SLORs) and evaluate their characteristics, the distribution of applicants’ ratings, correlation between SLOR domain ratings and conventional application metrics, and potential biases. null null null Methods null We evaluated all applications submitted to our residency program for the 2020–2021 urology match. Two main formats of SLOR were identified. We extracted application characteristic...
#2Jacob E. TallmanH-Index: 1
Last. Xiao-Cheng WuH-Index: 51
view all 19 authors...
#1Michael Staehler (LMU: Ludwig Maximilian University of Munich)H-Index: 58
#2Dena BattleH-Index: 5
Last. David F. Penson (VUMC: Vanderbilt University Medical Center)H-Index: 82
view all 5 authors...
To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications. An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure. Five-hundred-and-thirty-nine patients (39%:5...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.